Search
EHA, in partnership with ISTH, award two fellows to support global educational opportunities
EHA and the International Society on Thrombosis and Hemostasis (ISTH) jointly awarded two joint ISTH-EHA Training Fellowships to Araci Rondon (The Netherlands) and Dianne van der Wal (Australia).
Read moreEHA-Baltic Hematology Tutorial in Estonia provides European-level expertise to local hematologists
EHA partnered with three Baltic societies on October 18 and 19 to provide European-level expertise to local hematology trainees and experienced hematologists.
Read moreEHA and Polish Society’s third tutorial together focused on myeloid and lymphoid leukemias
Seventy-five participants from Europe and the Middle East learned about the advances in biology, genetic characteristics, diagnostic approaches and therapy of leukemias during the EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias in Warsaw, Poland.
Read moreAdding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read moreEHA supports the proposal for a Regulation on the European Health Data Space (EHDS)
On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.
Read moreEHA has joined the European Cancer Organisation - a perfect match on objectives and prioritization
The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level.
Read moreHelping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
Read moreAddition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
Read moreEHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia
Dates: April 12-14, 2018
Location: Barcelona, Spain
Chair: N Gökbuget
Co-chairs: R Bassan, H Dombret, A Fielding, R Foà, D Hoelzer, JM Ribera
EHA and the EHA Scientific Working Group on Acute Lymphoblastic Leukemia are organizing their second EHA-SWG Scientific Meeting on Acute Lymphoblastic Leukemia.…
EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease
November 10-11, 2022 | Bordeaux, France
Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- »